Atlanta 1/9/2014 4:00:00 AM
News / Finance

MissionIR Features VolitionRx (VNRX) in Exclusive Interview

MissionIR would like to highlight VolitionRx Ltd. (OTCQB: VNRX), a life sciences company focused on bringing to market its inexpensive, accurate, and scalable cancer detection blood tests. The company intends to use its NuQR suite of products to fill a looming void in cancer diagnostic testing, for which there currently is only one blood test in common clinical use. NuQR is based on VolitionRx's proprietary NucleosomicsR technology, capable of measuring and identifying nucleosome structures in the blood. The company has secured strong intellectual property protection for its products, further strengthened by patent applications in the United States, Europe and worldwide. Following ongoing clinical trials and regulatory approval, VolitionRx will market its diagnostic and screening tests for individual cancers under the NuQR brand.

In the company’s news,

MissionIR announced that a new audio interview with VolitionRx, Ltd. President and CEO Cameron Reynolds had been published online. The entirety of the interview can be found at:

VolitionRx is a publicly held cancer diagnostics company that is concentrating its efforts on bringing to market inexpensive, accurate, and minimally invasive cancer detection blood tests that it has developed. Initially, the company is focusing on marketizing diagnostic testing for colorectal cancer, which is the third most commonly diagnosed cancer in the United States. Recently, a clinical study of some 16,000 patients was started to assess the accuracy of the company’s blood test. Other plans are in place to develop diagnostic testing for other cancers in addition to the detection of colorectal cancer.

Commenting on this development, Mr. Reynolds said, “Being a small company and colorectal being a multi-billion dollar market in itself, we’re focusing on getting product out for that. But it’s certainly something we’d be very keen to expand into other cancers as soon as we’re through the process of developing this diagnostic for colorectal cancer.”

He also discussed the strong accuracy of the company’s blood-based tests as well as his own professional background and those of the company’s management and scientific teams. Mr. Reynolds himself holds over 17 years’ entrepreneurial executive expertise in mining and biotechnology companies, with extensive experience in the management, structuring, and strategic planning of start-up companies. As a whole, both teams collectively have decades of related experience and industry success.

The company’s President and CEO then touched upon recent company milestones and expectations and goals for 2014. He commented, “It’s been a very pivotal year for the company and next year we’ll begin to get the results from this large clinical trial coming through, so there are some very large data points coming in the first few quarters of the year, which if they continue to go well will be transformational for the company and really put us on the map as a very stable, technologically superior platform for detecting colorectal cancer.”

Mr. Reynolds then continued, “We’re beginning the process next year of beginning legal ability to sell our tests in Europe and start the process of U.S. FDA trials.”

Wrapping it all up, he then noted that VolitionRx aims to uplist to a major stock exchange in the second half of 2014 to fully access capital markets and continue company growth.

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit

To connect with MissionIR via Facebook, please visit

To connect with MissionIR via Twitter, please visit

Please read FULL disclaimer on the MissionIR website:

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.